Transformative Progress in Clinical Stage Cell Therapy
RoosterBio Inc., renowned for its supply of human mesenchymal stem/stromal cells (MSCs), has joined forces with Secretome Therapeutics to revolutionize the therapeutic landscape with their recent successful completion of large-scale bioreactor production for STM-01, a promising candidate in cell therapy.
Partnership Launching Innovative Production Methods
The collaboration, which commenced with RoosterBio initiating a comprehensive development program, focused on establishing a cGMP-compatible bioreactor system aimed at producing STM-01. This project emphasizes a shift from traditional 2D flask-based processes to a more efficient 50-liter bioreactor, greatly enhancing productivity and scalability. The phase I clinical trials of STM-01 target heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM). This critical evolution facilitates more effective manufacturing processes, allowing for higher yield and reduced production costs, thus, paving the way for advanced therapy accessibility.
Innovative Techniques Driving Efficiency
A cornerstone of the STM-01 production process is RoosterBio’s proprietary cGMP-grade cell expansion medium, RoosterNourish™-MSC-CC, accompanied by the crucial bioreactor feed, RoosterReplenish™-MSC-CC. This innovative fed-batch media system is particularly designed for the efficient and high-yield production of cell therapies in bioreactor settings. The streamlined methodology aids in simplifying manufacturing processes while maintaining affordability and quality in the creation of advanced therapeutic products like STM-01.
Leadership Insights on Innovation
Tim Kelly, the CEO of RoosterBio, expressed enthusiasm regarding the partnership, highlighting the company's dedication to developing scalable and cost-effective production solutions for cell and exosome therapeutics. His words capture the spirit of collaboration and progress: “It’s gratifying to contribute to making transformative therapies like STM-01 more accessible to patients suffering from heart failure.”
Overcoming Production Challenges in Cell Therapy
The scale-up of stem cell-based therapeutics has historically posed challenges in the pathway towards FDA approval; hence, addressing manufacturing intricacies has been a priority for Secretome Therapeutics from its inception three years ago. Vinny Jindal, President and CEO of Secretome, noted the significance of RoosterBio's expertise in enabling successful production scalability. He underscored their shared goals for future endeavors, expressing eagerness to collaborate on other pipeline products.
Future Outlook and Additional Developments
RoosterBio and Secretome are not resting on their laurels with STM-01; they are also engaging in the development of STM-21, a secretome sourced from STM-01. This promising avenue is under investigation for its applications in treating neurological conditions like amyotrophic lateral sclerosis (ALS) and diabetic neuropathy, along with potential benefits for skin conditions resulting from burns and inflammation. The ongoing processes for STM-21 follow a similar path, involving the establishment of a 50L bioreactor-based process.
Company Missions and Goals
RoosterBio aims to expedite the development of human MSCs and extracellular vesicle products, essential in advancing the rapid implementation of scalable therapies. By offering high-quality MSCs, potent bioprocess media, and comprehensive bioprocessing knowledge, they propel therapeutic developers swiftly from the initial concept stages to first-in-human testing and eventually to commercial manufacturing—ensuring both reduced costs and maximized productivity.
About RoosterBio
RoosterBio is committed to the mission of accelerating cellular therapy developments utilizing a suite of expertly crafted products and processes. Their focus remains on creating safer, effective advanced therapies that can reach a global audience at an enhanced pace.
About Secretome Therapeutics
Secretome Therapeutics is at the forefront of developing groundbreaking regenerative medicines sourced from neonatal cardiac progenitor cells (nCPC). Their commitment to harnessing cell-secreted bioactive factors aims to address significant medical needs, providing a new class of off-the-shelf biologic therapies that activate the body’s inherent repair mechanisms.
Frequently Asked Questions
What is the main goal of the partnership between RoosterBio and Secretome Therapeutics?
The partnership aims to enhance the production efficiency of the stem cell therapy candidate STM-01, facilitating clinical trials focusing on heart-related conditions.
What is STM-01?
STM-01 is an innovative therapy in clinical trials designed to address issues like heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM).
How does the bioreactor production process benefit manufacturing?
The bioreactor production process allows for greater scalability and cost-effectiveness compared to traditional 2D methods, ultimately improving productivity and reducing time to market.
What future products are RoosterBio and Secretome working on?
In addition to STM-01, they are advancing STM-21, which focuses on therapeutic applications for neurological conditions and inflammatory skin issues.
What are the key components used in the production of STM-01?
The key components include RoosterNourish™-MSC-CC for cell expansion and RoosterReplenish™-MSC-CC for effective bioreactor feeding.
